患者与GLP1-RAs的经验 - 一个系统的审查
Christoffer Kraul Ibsen1, Marius Brostrøm Kousgaard1, Sofie Olsen1
1Center for General Practice, University of Copenhagen, Copenhagen, Denmark.
Scandinavian journal of primary health care
|March 12, 2025
概括
使用类似葡萄糖-1受体激活剂 (GLP1-RAs) 治疗肥胖的患者接受减肥的副作用,并报告改善了健康状况. 了解患者对这些流行的肥胖药物的体验至关重要.
科学领域:
- 代谢障碍 代谢障碍 代谢障碍
- 药理学 药理学是指药理学的学科.
- 患者报告的结果.
背景情况:
- 肥胖是一个重要的公共卫生问题,有效的治疗方法有限.
- 类似葡萄糖-1受体激动剂 (GLP1-RAs) 显示出显著减肥的前景.
- 患者对GLP1-RAs的体验尚不清楚.
研究的目的:
- 对GLP1-RAs.患者体验的现有研究进行系统审查.
- 综合关于患者关于GLP1-RAs对肥胖管理的观点的定性和定量数据.
主要方法:
- 在主要数据库 (PubMed,PsycINFO,Embase,社会学摘要) 进行全面的文献搜索.
- 包括成人GLP1-RA使用者的研究,不包括精神疾病或PCOS等特定疾病.
- 对9项选定的研究 (定性,RCT,评论,调查) 进行主题分析,以综合发现.
主要成果:
- 患者耐受不良事件,如胃肠道问题,成功减肥.
- 通过GLP1-RAs实现的减肥可以改善身体功能和日常生活.
- 患者的体验在药物可用性,渴望管理和性别特异性益处方面各不相同.
结论:
- 尽管对GLP1-RA患者体验有很高的需求,但对GLP1-RA患者体验的定性研究是有限的.
- 进一步的研究是必不可少的,以充分理解与GLP1-RAs的短期和长期患者的旅程.
- 了解患者的观点可以优化肥胖治疗策略.
相关概念视频
Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
Assessment of the Gastrointestinal System I: Subjective Data
160
Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
160
Oral Hypoglycemic Agents: Glinides
148
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
148
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
167
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
167
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178


